Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma

Journal of Laryngology and Otology

Volumn 117, Issue 3, 2003, Pages 190-194

  Deng, Yan Fei ^a,b   Chen, Ping ^a   Lin, Yong Zhi ^a   Le, Jia Zhen ^a   Wu, Xiao Li ^a   Yu, Ming Qiang ^a   Zhuang, Pei Yun ^a   Gao, Ming Hua ^a  

^a XIAMEN UNIVERSITY   (China)

^b ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Carcinoma; Head and Neck Neoplasms; Immunoassay; Squamous Cell

Indexed keywords

CYTOKERATIN 19 FRAGMENT; TUMOR MARKER;

ADULT; AGE; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRINKING BEHAVIOR; FEMALE; FOLLOW UP; GENDER; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SMOKING; SQUAMOUS CELL CARCINOMA;

ADULT; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CHEMILUMINESCENT MEASUREMENTS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOASSAY; KERATINS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 0037335252     PISSN: 00222151     EISSN: None     Source Type: Journal    
DOI: 10.1258/002221503321192485     Document Type: Article

References (22)

1. Mork J. Forty years of monitoring head and neck cancer in Norway: no good news. Anti-Cancer Res 1998;18:3705-8
2. Nakata B, Ogawa Y, Ishikawa T, Ikeda T, Kato Y, Nishino H, et al. Serum CYFRA 21-1 is one of the most reliable tumour markers for breast carcinoma. Cancer 2000;89:1285-90
3. Mady EA. Cytokeratins as serum markers in Egyptian bladder cancer: a comparison of CYFRA 21-1, TPA and TPS. Int J Biol Markers 2001;16:130-5
4. Ogawa T, Tsurusako Y, Kimura N, Nishioka S, Akagi H, Nishizaki K, et al. Comparison of tumor markers in patients with squamous cell carcinoma of the head and neck. Acta Otolaryngol Suppl 1999;540:72-6
5. Rao VR, Krishnamoorthy L, Kumaraswamy SV, Ramaswamy G. Circulating levels in serum of total sialic acid, lipid-associated sialic acid, and fucose in precancerous lesion and cancer of the oral cavity. Cancer Detect Prev 1998;22:237-40
6. Vural E, Alexiou M, Hunt J 2nd, Korourian S, Hanna E. Is glutathione-S-transferase-pi expression a reliable predictor of chemoradiation response in cancer of the head and neck? Am J Otolaryngol 2001;22:257-60
7. Bhattathiri VN. Relation of erythrocyte and iron indices to oral cancer growth. Radiother Oncol 2001;59:221-6
8. Makrantonakis P, Pectasides D, Aggouridakis C, Visvikis A, Daniilidis J, Fountzilas G. Squamous cell carcinoma antigen, circulating immune complexes, and immuno-globulins in monitoring squamous cell carcinoma of head and neck: a study of the Hellenic co-operative oncology group (HeCOG). Am J Clin Oncol 1999;22:542-9
9. Quon H, Liu FF, Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001;23:147-9
10. Karnak D, Ulubay G, Kayacan O, Beder S, Ibis E, Oflaz G. Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas. Lung 2001;179:57-65
11. Maass JD, Hoffmann-Fazel A, Goeroegh T, Hoffmann M, Meyer JE, Gottschlich S, et al. Cyfra 21-1: a serological help for detection of distant metastases in head and neck cancer. Anti-Cancer Res 2000;20:2241-3
12. Bodenmueller H. The biochemistry of CYFRA 21-1 and other cytokeratin-tests. Scand J Clin Lab Invest Suppl 1995;221:60-6
13. Fujita J, Dohmoto K, Hojo S, Ueda Y, Bandoh S, Yang Y, et al. The point mutation in the promoter region and the single nucleotide polymorphism in exon 1 of the cytokeratin 19 gene in human lung cancer cell lines. Lung Cancer 2001;34:387-94
14. Dohmoto K, Hojo S, Fujita J, Yang Y, Ueda Y, Bandoh S, et al. The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA 21-1) in human lung cancer cell lines. Int J Cancer 2001;91:468-73
15. Lin WY, Yen TC, Cheng KY, Wang SJ. The value of CYFRA 21-1, a new tumour marker, in nasopharyngeal carcinoma. Neoplasma 1998;45:21-4
16. Nagler RM, Barak M, Peled M, Ben-Aryeh H, Filatov M, Laufer D. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma. Cancer 1999;85:1018-25
17. Banal A, Hacene K, Berthelot-Ruff E, Mahe E, Fontana X, Pichon MF. Comparison of Cyfra 21-1 and SCC assays in head and neck tumours. Tumour Biol 2001;22:27-35
18. Wollenberg B, Jan V, Schmit UM, Hofmann K, Stieber P, Fathe-Moghadam A. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer. Anti-Cancer Res 1996;16:3117-24
19. Goumas PD, Mastronikolis NS, Mastorakou AN, Vassilakos PJ, Nikiforidis GC. Evaluation of TAT1 and CYFRA 21-1 in patients with head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 1997;59:106-14
20. Sanchez-Carbayo M, Espasa A, Chinchilla V, Herrero E, Megias J, Mira A, et al. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin Chem 1999;45:1944-53
21. Kawaguchi H, Ohno S, Miyazaki M, Hashimoto K, Egashira A, Saeki H, et al. CYFRA 21-1 determmation in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences. Cancer 2000;89: 1413-7
22. Gonzalez Sanchez E, Lopez-Rios Velasco, J, Calvo Boizas E, Garcia-Talavera Fernandez JR, Martin Rodriguez M, Munoz Herrera A, et al. Study of Cyfra 21-1 as a new tumour marker for the diagnosis of epidermoid carcinoma of the head and neck. Acta Otorrinolaringol. Esp 1999;50: 85-9